843666-40-0

Basic information

• Product Name: OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER
• Synonyms: OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER;18-(tert-Butoxy)-18-oxooctadecanoic acid;18-(tert-Butoxy)-18-oxostearic acid, tert-Butyl 17-carboxyheptadecanoate;18-(tert-Butoxy);-18-oxooctadecanoic acid;Octadecanedioic acid,1-(1,1-dimethylethyl) ester;18-[(2-methylpropan-2-yl)oxy]-18-oxooctadecanoic acid;Octadecanedioic acid mono(1,1-dimethylethyl) ester
• CAS NO: 843666-40-0
• Molecular Formula: C₂₂H₄₂O₄
• Molecular Weight: 370.58
• Mol File: 843666-40-0.mol
• Article Data: 11

Chemical Properties

• Melting Point: 68 °C
• Boiling Point: 470.7±18.0 °C(Predicted)
• Appearance: /
• Density: 0.950±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 4.78±0.10(Predicted)
• CAS DataBase Reference: OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER(843666-40-0)
• EPA Substance Registry System: OCTADECANEDIOIC ACID MONO-TERT-BUTYL ESTER(843666-40-0)

Safety Data

• Hazardous Substances Data: 843666-40-0(Hazardous Substances Data)

Usage

Uses

18-(tert-Butoxy)-18-oxooctadecanoic Acid is used to engineer long-acting, potent exendin-4 based GLP-1 analog for microstructure-based transdermal delivery for glycemic control.

Upstream product

• 41059-02-3 9-bromononanoic acid 
• 821-38-5 1,14-tetradecanedioic acid 
• 75-65-0 tert-butyl alcohol 
• 505-54-4 thapsic acid 
• 871-70-5 octadecanedioic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 45270-18-6 1,18-octadecanedioyl dichloride 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 

Downstream Products

• 843666-34-2 octadecanedioic acid tert-butyl ester-2,5-dioxopyrrolidin-1-yl ester 
• 1118767-15-9 17-(4-(S)-1-tert-butoxycarbonyl-3-{2-[2-({2-[2-(2,5-dioxopyrrolidin-1-yloxycarbonylmethoxy)ethoxy]ethylcarbamoyl}methoxy)ethoxy]ethylcarbamoyl}propylcarbamoyl)heptadecanoic acid tert-butyl ester 

Relevant articles and documents

Preparation method of long-chain aliphatic dicarboxylic acid mono-tert-butyl ester

The invention provides a method for obtaining the long-chain aliphatic dicarboxylic acid mono-tert-butyl ester through monohydrolysis of the long-chain aliphatic dicarboxylic acid di-tert-butyl ester by controlling the reaction conditions of monohydrolysis; and the raw material cost is low, the yield is high, the post-treatment method is simple, and the method is suitable for industrial production.

Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320

Recently, the first basal oral insulin (OI338) was shown to provide similar treatment outcomes to insulin glargine in a phase 2a clinical trial. Here, we report the engineering of a novel class of basal oral insulin analogues of which OI338, 10, in this publication, was successfully tested in the phase 2a clinical trial. We found that the introduction of two insulin substitutions, A14E and B25H, was needed to provide increased stability toward proteolysis. Ultralong pharmacokinetic profiles were obtained by attaching an albumin-binding side chain derived from octadecanedioic (C18) or icosanedioic acid (C20) to the lysine in position B29. Crucial for obtaining the ultralong PK profile was also a significant reduction of insulin receptor affinity. Oral bioavailability in dogs indicated that C18-based analogues were superior to C20-based analogues. These studies led to the identification of the two clinical candidates OI338 and OI320 (10 and 24, respectively).

GLP-1R AND GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE

This disclosure relates to the field of GLP-1R and GCGR agonists, formulations, and methods of using the same, including but not limited to dual agonist peptides of any of SEQ ID NOS. 1-10 or 12-27 conjugated to a non-ionic glycolipid surfactant.